SuperworthRapid Micro Biosystems RPID
- Market cap
- $39.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $35.2M
- +16% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −103.2%
Rapid Micro Biosystems trades at 1.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $35.2M over the last twelve months, up 16% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.1M+30% | $6.3M+45% | $5.6M+11% | $6.6M+32% | $7.6M+24% | $8.2M+30% | $7.2M+28% | $7.3M+10% | $7.8M+3% | $11.3M+37% | $8M+11% | $8.1M+11% | |
| Cost of revenue | $7.8M+3% | $6.5M−7% | $7.1M+5% | $6.8M−1% | $7M−10% | $7.2M+11% | $6.8M−5% | $7M+3% | $7.1M+2% | $11.6M+60% | $7.6M+12% | $6.8M−2% |
| Gross profit | −$1.6M−42% | −$172K−93% | −$1.5M−15% | −$189K−90% | $622K | $981K | $404K | $275K | $696K+12% | −$328K | $371K−8% | $1.2M+341% |
| R&D | $3.1M+5% | $3.3M−3% | $3.8M+22% | $3.7M+16% | $3.6M+16% | $3.4M+3% | $3.6M−6% | $3.2M−14% | $3.5M−2% | $3.2M−5% | $3.4M−7% | $3.3M+3% |
| SG&A | $9.7M−13% | $8.7M−23% | $8.9M−10% | $9.4M−5% | $9.1M−7% | $7.8M−10% | $8.4M−5% | $9.2M−3% | $8.5M−6% | $8.7M+11% | $10.9M+29% | $10.2M+11% |
| −$14.4M−14% | −$12.2M−29% | −$14.3M−4% | −$13.4M−11% | −$12M−17% | −$10.2M−16% | −$11.7M−18% | −$12.1M−9% | −$11.4M−6% | −$12.2M+19% | −$13.9M+19% | −$12.3M+1% | |
| Interest expense | n/a | n/a | n/a | n/a | $11K | $12K | $12K | $12K | $393K+3473% | $673K+5508% | $639K+5225% | $646K+5283% |
| Pre-tax income | −$13.4M−18% | −$11.2M−32% | −$13.3M−4% | −$12.6M−10% | −$11.3M−16% | −$9.7M−13% | −$11.3M−16% | −$11.8M−6% | −$11.5M+2% | −$12.5M+29% | −$14.3M+27% | −$12.9M+9% |
| $10K+43% | $8K+14% | $3K−57% | $15K+150% | $13K+30% | −$9K | $7K+133% | $11K−27% | $8K−39% | $14K | $8K+14% | $45K+309% | |
| Net income | −$13.4M−18% | −$11.2M−32% | −$13.3M−4% | −$12.6M−10% | −$11.3M−15% | −$9.7M−14% | −$11.3M−16% | −$11.9M−6% | −$11.5M+2% | −$12.5M+29% | −$14.3M+27% | −$12.9M+9% |
| −$0.31−18% | −$0.26−33% | −$0.31−3% | −$0.29−12% | −$0.26−16% | −$0.22−15% | −$0.26−16% | −$0.27−7% | −$0.26+0% | −$0.28+27% | −$0.31+19% | −$0.27+0% | |
| 43.1M+1% | 43.1M+1% | 43.2M+1% | 43.6M+1% | 43.7M+1% | 43.8M+2% | 44M+2% | 44.6M+2% | 45M+3% | 45.1M+3% | 45.4M+3% | 48.3M+8% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them. 22 periods, Q2 FY20 to Q4 FY25: not printed by the filing, worked out from its own lines.
R&D: Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Rapid Micro Biosystems' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RPIDRapid Micro Biosystems | $39.1M | n/m | n/a | 1.1× | +16% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on Rapid Micro Biosystems
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .